- Home
- BLNK vs TCRX Comparison
BLNK vs TCRX Comparison
Compare BLNK & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLNK
- TCRX
- Stock Information
- Founded
- BLNK 2009
- TCRX 2018
- Country
- BLNK United States
- TCRX United States
- Employees
- BLNK N/A
- TCRX N/A
- Industry
- BLNK Industrial Specialties
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- BLNK Consumer Discretionary
- TCRX Health Care
- Exchange
- BLNK Nasdaq
- TCRX Nasdaq
- Market Cap
- BLNK 100.0M
- TCRX 91.7M
- IPO Year
- BLNK N/A
- TCRX 2021
- Fundamental
- Price
- BLNK $0.94
- TCRX $1.80
- Analyst Decision
- BLNK Buy
- TCRX Strong Buy
- Analyst Count
- BLNK 8
- TCRX 6
- Target Price
- BLNK $2.54
- TCRX $9.50
- AVG Volume (30 Days)
- BLNK 2.4M
- TCRX 267.1K
- Earning Date
- BLNK 08-18-2025
- TCRX 08-12-2025
- Dividend Yield
- BLNK N/A
- TCRX N/A
- EPS Growth
- BLNK N/A
- TCRX N/A
- EPS
- BLNK N/A
- TCRX N/A
- Revenue
- BLNK $109,383,000.00
- TCRX $6,961,000.00
- Revenue This Year
- BLNK N/A
- TCRX $159.20
- Revenue Next Year
- BLNK $33.41
- TCRX N/A
- P/E Ratio
- BLNK N/A
- TCRX N/A
- Revenue Growth
- BLNK N/A
- TCRX N/A
- 52 Week Low
- BLNK $0.63
- TCRX $1.02
- 52 Week High
- BLNK $2.32
- TCRX $6.23
- Technical
- Relative Strength Index (RSI)
- BLNK 47.63
- TCRX 55.11
- Support Level
- BLNK $0.90
- TCRX $1.60
- Resistance Level
- BLNK $0.96
- TCRX $1.87
- Average True Range (ATR)
- BLNK 0.05
- TCRX 0.11
- MACD
- BLNK -0.01
- TCRX -0.00
- Stochastic Oscillator
- BLNK 47.67
- TCRX 62.50
About BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.